CURRENT POSSIBILITIES OF USING RADIOPHARMACEUTICALS TO EVALUATE CEREBRAL BLOOD FLOW
https://doi.org/10.20862/0042-4676-2017-98-1-44-49
Abstract
A comparison of the possibilities of using various neurotropic radiopharmaceuticals for scintigraphic evaluation of cerebral perfusion. In the whole range of radiopharmaceuticals used to diagnose cerebral blood flow disorders, there are Ceretec (99mTc-hexamethylpropyleneamine) and Neurolite (N,N-1,2-ethylenediylbis-L-cysteine-diethyl ether), which are the most optimal agents. Due to their high cost and related radiation exposure, the radiopharmaceuticals 123І-IMP (123I-isopropyl-iodoamphetamine) and 201Tl-DDC (diethyldithiocarbamate) labeled with thallium-201 virtually minimize the possibilities of being used in daily clinical practice. Fixation of 99mTc-DDC in the brain proves to be short-term, which is insufficient for tomoscintigraphy studies. Literature has been sought in the Scopus, Web of Scince, Pubmed, EMBASE, and Russian Science Citation Index databases.
About the Authors
N. Yu. N.Yu. Efimova
Сardiology Research Institute, ul. Kievskaya, 111a, Tomsk, 634012, Russian Federation;
Tomsk Polytechnic University, prospect Lenina, 30, Tomsk, 634050, Russian Federation
Russian Federation
Russian Federation
MD, PhD, DSc, Senior Researcher
N. G. Krivonogov
Сardiology Research Institute, ul. Kievskaya, 111a, Tomsk, 634012, Russian Federation
Russian Federation
Russian Federation
MD, PhD, DSc, Senior Researcher
Yu. B. Lishmanov
Сardiology Research Institute, ul. Kievskaya, 111a, Tomsk, 634012, Russian Federation;
Tomsk Polytechnic University, prospect Lenina, 30, Tomsk, 634050, Russian Federation
Russian Federation
Russian Federation
MD, PhD, DSc, Professor, Corresponding Member of Russian Academy of Sciences
I. Yu. Efimova
Сardiology Research Institute, ul. Kievskaya, 111a, Tomsk, 634012, Russian Federation
Russian Federation
Russian Federation
MD, PhD, DSc, Scientific Secretary
References
1. Лишманов Ю.Б., Чернов В.И. Национальное руководство по радионуклидной диагностике. Томск: STT; 2010. [Lishmanov Yu.B., Chernov V.I. National Guide on radionuclide diagnostics. Tomsk: STT; 2010 (in Russ.).]
2. Shiraishi H., Chang C.C., Kanno H., Yamamoto I. The relationship between cerebral blood flow and cognitive function in patients with brain insult of various etiology. J. Clin. Neurosci. 2004; 11 (2): 138–41.
3. Стародубцева О.С., Бегичева С.В. Анализ заболеваемости инсультом с использованием информа-ционных технологий. Медицинские науки. 2012; 8: 424–7. [Starodubtseva O.S., Begicheva S.V. Analysis of the incidence of stroke with the use of information technology. Meditsinskie Nauki (Medical Sciences, Russian journal). 2012; 8: 424–7 (in Russ.).]
4. Ярошевский С.П., Ефимова И.Ю., Астанина И.А., Ефимова Н.Ю., Плотников М.П. Комплексная лучевая оценка реактивности сосудов головного мозга у пациентов с гемодинамически значимым стенозом сонных артерий. Бюллетень экспериментальной биологии и медицины. 2001; Прил. 1: 113–6. [Yaroshevskiy S.P., Efimova I.Yu., Astanina I.A., Efimova N.Yu., Plotnikov M.P. Complex assessment of radiation reactivity of cerebral vessels in patients with hemodynamically significant carotid steno-sis. Byulleten’ Eksperimental’noy Biologii i Meditsiny (Bulletin of Experimental Biology and Medicine, Russian journal). 2001; Suppl. 1: 113–6 (in Russ.).]
5. Лишманов Ю.Б., Завадовский К.В., Ефимова Н.Ю., Криво-ногов Н.Г., Ефимова И.Ю., Веснина Ж.В. и др. Возможности ядерной медицины в диагностике сердечно-сосудистых заболеваний. Сибирский медицинский журнал. 2015; 30 (2): 21–9. [Lishmanov Yu.B., Zavadovsky K.V., Efimova N.Yu., Krivonogov N.G., Efimova I.Yu., Vesnina Zh.V. et al. The possibilities of nuclear medicine in the diagnosis of cardiovascular diseases. Sibirskiy Meditsinskiy Zhurnal (Siberian Journal of Medicine, Russian journal). 2015; 30 (2): 21–9 (in Russ.).]
6. Verhoeff N.P.L., Buell U., Cos-ta D.C., Kirsch G. Basics and recommendations for brain SPECT.J. Nucl. Med. 1992; 31: 114–31.
7. Скуридин В.С. Методы и технологии получения рафиофармпрепаратов: Учебное пособие. Томск: Томский политехнический университет; 2013. [Skuridin V.S. Methods and technics of reception of radiopharmaceuticals: Tutorial. Tomsk: Tomsk Polytechnic University; 2013 (in Russ.).]
8. Chen Y.J., Deutsch G., Satya R., Liu H., Mountz J. A semi-quantitative method for correlating brain disease groups with normal controls using SPECT: Alzheimer's disease versus vascular dementia. Comput. Med. Imaging Graph. 2013; 37 (1): 40–7.
9. Orimo S. Differential diagnosis of dementia with lewy bodies. Brain Nerve. 2015; 67 (4): 413–25.
10. Pupj A., Cristofaro M.T., Bacciottini L. An analysis of the arterial input curve for Tc-99m-HMPAO: quantification of rCBF using SPECT. J. Nucl. Med. 1991; 32 (8): 1501–6.
11. Serrano-Vicente J., Duran-Barquero C., Garcia-Bernardo L., Dominguez-Grande M., Infante-Torre J., Rayo-Madrid J. Bilateral alien hand syndrome in cerebrovascular disease: CT, MR, CT angiography, and 99mTc-HMPAO-SPECT findings. Clin. Nucl. Med. 2015; 40 (3): 211–4.
12. Zhu L., Ploessl K., Kung H.F. PET/SPECT imaging agents for neurodegenerative diseases. Chem. Soc. Rev. 2014; 43 (19): 6683–91.
13. Santra A., Sinha G.K., Neogi R., Thukral R.K. 99mTc-hexamethyl propyleneamine oxime brain perfusion single photon emission computed tomography in characterization of dementia: an initial experience in Indian clinical practice. World J. Nucl. Med. 2014; 13 (2): 120–7.
14. Oono M., Uno H., Umesaki A., Nagatsuka K., Kinoshita M., Narito-mi H. Severe and prolonged ictal paresis in an elderly patient. Epilepsy Behav Case Rep. 2014; 2: 105–7.
15. Sequeira K.M., Tabesh A., Sainju R.K., DeSantis S., Naselaris T., Joseph E. et al. Perfusion network shift during seizures in medial temporal lobe epilepsy. PLoS One. 2013; 8 (1): e53204.
16. Hung J.C., Volkert W.A., Hol-mes R.A. Stabilisation of technetium-99m-d,l-HMPAO using gentisic acid. Nucl. Med. Biol. 1989; 16: 675.
17. Asl M.T., Yousefi F., Nemati R., Assadi M. 99mTc-ECD brain perfusion SPECT imaging for the assessment of brain perfusion in cerebral palsy (CP) patients with evaluation of the effect of hyperbaric oxygen therapy. Int. J. Clin. Exp. Med. 2015; 8 (1): 1101–7.
18. Su X., Zheng K., Ma Q., Huang J., He X., Chen G. et al. Effect of local mild hypothermia on regional cerebral blood flow in patients with acute intracerebral hemorrhage assessed by 99mTc-ECD SPECT imaging. J. Xray Sci. Technol. 2015; 23 (1): 101–9.
19. Kameyama M. Lassen's equation is a good approximation of permeabi- lity-surface model: new values for 99mTc-HMPAO and 99mTc-ECD.J. Cereb. Blood Flow Metab. 2014; 34 (7): 1157–61.
20. Leveille J., Demonceau G., De-Roo M. Charakterisation of technetium-99m-1,1-ECD for brain perfusion imaging, part 2: Biodistribution and brain imaging in humans. J. Nucl. Med. 1989; 30: 1902–10.
21. Hayashida K., Nishimura T., Imakita S., Uehara T. Favorable biodistribution of 99mTc-ECD for brain SPECT comparing with 123I-IMP using alternative body scan. Ann. Nucl. Med. 1992; 6 (4): 229–33.
22. Tsuchida T., Nishizawa S., Yonekura Y. et al. SPECT images of technetium-99m-ethyl cysteinate dimer in cerebrovascular diseases: comparison with other cerebral perfusion tracers and PET. J. Nucl. Med. 1994; 35 (1): 27–31.
23. Kung H.F. New Technetium-99m Labelled Brain Perfusion Imaging Agents. Sem. Nucl. Med. 1990; 22 (2): 150–8.
24. Verbruggen A.M. Radiopharmaceuticals: state of art. Eur. J. Nucl. Med. 1990; 17 (6–8): 346–64.
25. Краснокутская Е.А., Трусова М.Е., Гиберт Н.С., Филимонов В.Д. Синтез 4-йодантипирина йодированием без растворителя в условиях механической активации. Химико-фармацевтический журнал. 2007; 41 (3): 35–6. [Krasnokutskaya E.A., Trusova M.E., Gibert N.S., Filimonov V.D. Synthesis of 4-Jodantipyrin iodization without solvent under mechanical activation. Khimiko-Farmatsevticheskiy Zhurnal (Chemical-Pharmaceutical Journal, Russian Journal). 2007; 41 (3): 35–6 (in Russ.).]
26. Abe S., Kato K., Takahashi Y., Fujita N., Fujita N., Yamashita M. et al. Estimation of 123I-IMP arterial blood activity using 123I-IMPacquisition data from the lungs and brain without any blood sampling: validation of its usefulness for quantification of regional cerebral blood flow. Clin. Nucl. Med. 2012; 37 (3): 258–63.
27. Iida H., Itoh H., Bloomfield P.M., Munaka M., Higano S., Muraka-mi M. et al. A method to quantitate cerebral blood flow using a rotating gamma camera and iodine-123 iodoamphetamine with one blood sampling. Eur. J. Nucl. Med. 1994; 21 (10): 1072–84.
28. Sunderman F.W. Diethyldithiocarbamate therapy of thallotoxicosis. Am. J. Med. Sci. 1967; 253: 209–20.
29. Hsia Y.E. Hepatolenticular degeneration: the comparison effectiveness of D-penicillamine, potassium sulphide and diethyldithiocarba-mate as decoppering agents. J. Pediat. 1966; 68: 921–6.
30. Vyth A., Fennema P., van der Shoot J. Tl-201-diethil-dithiocarbamate: a possible radiopharmaceutical for brain imaging. Pharm. Weekbl (Sci). 1983; 5: 213–6.
31. Van Royen E.A., de Bruine J.F., Hill T.C. Cerebral blood flow imaging with thallium-201 diethylditiocarbamate SPECT. J. Nucl. Med. 1987; 28 (2): 178–83.
32. Lear J.L. Autoradiographic evaluation of 99m-Tc-hexamethylpropylenamioxime (HMPAO) and Tl-201 diethyldithiocarbamate (DDC) as tracers for cerebral blood flow. Nucl. Med. 1987; 26: 32.
33. Costa D.C., Lui D., Sinha A.K., Jarritt P.H., Ell P.J. Intracellular localisation of 99mTc-d,l-HMPAO and 201Tl-DDC in rat brain. Nucl. Med. Commun. 1989; 10: 459–66.
34. Limburg M., Hijdra A., de Bruine J.F., Verbeeten B.W.J. RCBFSPECT in Brain infarction: when does it predict outcome? J. Nucl. Med. 1991; 32: 382–7.
35. Ballinger J.R., Gerson B., Gulenchyn K.Y. Technetium-99m Dithiocarbamates as Potential Brain Agents: Evaluation of Aliphatic and Amine-containing Analogues. Nucl. Med. Biol. 1989; 16 (7): 721–5.
Review
For citations:
N.Yu. Efimova N.Yu., Krivonogov N.G., Lishmanov Yu.B., Efimova I.Yu. CURRENT POSSIBILITIES OF USING RADIOPHARMACEUTICALS TO EVALUATE CEREBRAL BLOOD FLOW. Journal of radiology and nuclear medicine. 2017;98(1):44-49. (In Russ.) https://doi.org/10.20862/0042-4676-2017-98-1-44-49
Views:
1948
Email this article 